Identification of an antibody fragment specific for androgen-dependent prostate cancer cells

BMC Biotechnology

Volumn 14, Issue 1, 2014, Pages

  Williams, Ryan M ^a,b   Hajiran, Cyrus J ^a   Nayeem, Sara ^a   Sooter, Letha J ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibody fragment; Library screening; Prostate cancer; scFv; Yeast

Indexed keywords

ANDROGEN-DEPENDENT; ANTIBODY FRAGMENT; LIBRARY SCREENING; PROSTATE CANCER CELLS; PROSTATE CANCERS; SCFV;

YEAST;

PROSTATE SPECIFIC MEMBRANE ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; IMMUNOGLOBULIN FRAGMENT;

ANDROGEN DEPENDENT PROSTATE CANCER CELL; ANTIBODY LIBRARY; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION CONSTANT; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER CELL LINE; ANTIBODY AFFINITY; CHEMISTRY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MALE; PROSTATIC NEOPLASMS;

EID: 84908059759     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-14-81     Document Type: Article

References (78)

1. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Chou R, Dana T, Bougatsos C, Fu R, Blazina I, Gleitsmann K, Rugge JB: Treatments for localized prostate cancer: systematic review to update the 2002 US preventive services task force recommendation. Evid Synthesis 2011, 91:12-05161-EF-1.
3. Yao SL, Lu-Yao G: Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst 1999, 91(22):1950-1956.
4. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 2001, 1(1):34-45.
5. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormoneresistant prostate cancer. Cancer 2006, 71(S3):1098-1109.
6. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993, 53(5):1037-1042.
7. Pienta KJ: Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001, 28(S15):3-7. Elsevier.
8. Pienta KJ, Smith DC: Advances in prostate cancer chemotherapy: a New Era Begins. CA Cancer J Clin 2005, 55(5):300-318.
9. Lin K, Croswell JM, Koenig H, Lam C, Maltz A: Prostate-specific antigenbased screening for prostate cancer: an evidence update for the US preventive services task force. Evid Synthesis 2011, 90:12-05160-EF-1.
10. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A: Screening for prostate cancer: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2011, 155(11):762.
11. Moyer VA: Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157(2):120-134.
12. Barry MJ: Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 2009, 360(13):1351-1354.
13. Pollack CE, Noronha G, Green GE, Bhavsar NA, Carter HB: Primary care Providers' response to the US preventive services task force draft recommendations on screening for prostate cancer. Arch Intern Med 2012, 172(8):668-670.
14. Woolf SH: Screening for prostate cancer with prostate-specific antigen- an examination of the evidence. N Engl J Med 1995, 333(21):1401-1405.
15. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr: Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006, 98(16):1128-1133.
16. Williams R, Naz R: Novel biomarkers and therapeutic targets for prostate cancer. Front Biosci (Schol Ed) 2010, 2:677-684.
17. Makarov DV, Loeb S, Getzenberg RH, Partin AW: Biomarkers for Prostate Cancer. In Annual Review of Medicine, Volume 60. Palo Alto: Annual Reviews; 2009:139-151.
18. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM: Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med 2012, 4(127):127rv3.
19. Morris KN, Jensen KB, Julin CM, Weil M, Gold L: High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A 1998, 95(6):2902-2907.
20. Guo KT, Ziemer G, Paul A, Wendel HP: CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci 2008, 9(4):668-678.
21. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA: Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989, 246(4935):1275-1281.
22. Gunneriusson E, Samuelson P, Uhlen M, Nygren PA, Stahl S: Surface display of a functional single-chain Fv antibody on staphylococci. J Bacteriol 1996, 178(5):1341-1346.
23. Boder ET, Wittrup KD: Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997, 15(6):553-557.
24. Figini M, Obici L, Mezzanzanica D, Griffiths A, Colnaghi MI, Winter G, Canevari S: Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res 1998, 58(5):991-996.
25. Jakobsen CG, Rasmussen N, Laenkholm AV, Ditzel HJ: Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78. Cancer Res 2007, 67(19):9507-9517.
26. Yu B, Ni M, Li WH, Lei P, Xing W, Xiao DW, Huang Y, Tang ZJ, Zhu HF, Shen GX: Human scFv antibody fragments specific for hepatocellular carcinoma selected from a phage display library. World J Gastroenterol 2005, 11(26):3985-3989.
27. Wang XX, Shusta EV: The use of scFv-displaying yeast in mammalian cell surface selections. J Immunol Methods 2005, 304(1-2):30-42.
28. Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, Yeung YA, Cochran JR, Heinzelman P, Colby D, Swers J, Graff C, Wiley HS, Wittrup KD: Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 2003, 21(2):163-170.
29. Jung ST, Jeong KJ, Iverson BL, Georgiou G: Binding and enrichment of Escherichia coli spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens. Biotechnol Bioeng 2007, 98(1):39-47.
30. Qiu J-K, Jung S-T, Georgiou G, Hang H-Y: Enrichment of Escherichia coli spheroplasts displaying scFv antibodies specific for antigens expressed on the human cell surface. Appl Microbiol Biotechnol 2010, 88(6):1385-1391.
31. Mazor Y, Van Blarcom T, Carroll S, Georgiou G: Selection of full-length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence-activated cell sorting screening. FEBS J 2010, 277(10):2291-2303.
32. Colcher D, Pavlinkova G, Beresford G, Booth B, Choudhury A, Batra S: Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 1998, 42(4):225-241.
33. Brockmann E-C, Cooper M, Strömsten N, Vehniäinen M, Saviranta P: Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions. J Immunol Methods 2005, 296(1):159-170.
34. Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T: Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 2007, 282(38):27659-27665.
35. Böldicke T, Tesar M, Griesel C, Rohde M, Gröne HJ, Waltenberger J, Kollet O, Lapidot T, Yayon A, Weich H: Anti-VEGFR-2 scFvs for Cell Isolation. Single-Chain Antibodies Recognizing the Human Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2/flk-1) on the Surface of Primary Endothelial Cells and Preselected CD34+ Cells from Cord Blood. Stem Cells 2001, 19(1):24-36.
36. Benedict CA, MacKrell AJ, Anderson WF: Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods 1997, 201(2):223-231.
37. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD: Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using Affinity-driven Selection. J Mol Biol 1996, 255(1):28-43.
38. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM: Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998, 58(3):485-490.
39. Jackson H, Bacon L, Pedley R, Derbyshire E, Field A, Osbourn J, Allen D: Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives. Br J Cancer 1998, 78(2):181.
40. Boder ET, Midelfort KS, Wittrup KD: Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci 2000, 97(20):10701-10705.
41. He J, Wang Y, Feng J, Zhu X, Lan X, Iyer AK, Zhang N, Seo Y, VanBrocklin HF, Liu B: Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med 2010, 51(3):427-432.
42. Gao C, Mao S, Ronca F, Zhuang S, Quaranta V, Wirsching P, Janda KD: De novo identification of tumor-specific internalizing human antibody- receptor pairs by phage-display methods. J Immunol Methods 2003, 274(1):185-197.
43. Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD: A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol 2006, 7(1):24.
44. Schrama D, Reisfeld RA, Becker JC: Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006, 5(2):147-159.
45. Zeng L, Rowland RG, Lele SM, Kyprianou N: Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 2004, 35(3):290-297.
46. Chen W, Pang B, Yang B, Zhou J, Sun Y: Differential proteome analysis of conditioned medium of BPH-1 and LNCaP cells. Chin Med J Beijing 2011, 124(22):3806-3809.
47. Chakrabarti R, Robles LD, Gibson J, Muroski M: Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines. Cancer Genet Cytogenet 2002, 139(2):115-125.
48. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 2000, 60(21):6134-6141.
49. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK: Expression profile of differentially-regulated genes during progression of androgenindependent growth in human prostate cancer cells. Carcinogenesis 2002, 23(6):967-976.
50. Chen Q, Watson JT, Marengo SR, Decker KS, Coleman I, Nelson PS, Sikes RA: Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Lett 2006, 244(2):274-288.
51. Yang M, Loda M, Sytkowski AJ: Identification of genes expressed differentially by LNCaP or PC-3 prostate cancer cell lines. Cancer Res 1998, 58(16):3732-3735.
52. Liu Z, Marquez M, Nilsson S, Holmberg AR: Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin. Oncol Rep 2009, 22(6):1451.
53. Aalinkeel R, Nair MPN, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, Schwartz SA: Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004, 64(15):5311-5321.
54. Okamura K, Koike H, Matsui H, Suzuki K: Gene Expression Profiles of Prostate Cancer Cell Lines, LNCaP, PC-3 and DU-145, Assessed by cDNA Microarray. Kitakanto Med J 2008, 58(4):363-369.
55. Rérole AL, Gobbo J, De Thonel A, Schmitt E, de Barros JPP, Hammann A, Lanneau D, Fourmaux E, Deminov O, Micheau O: Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res 2011, 71(2):484-495.
56. Robert R, Jacobin-Valat MJ, Daret D, Miraux S, Nurden AT, Franconi JM, Clofent-Sanchez G: Identification of human scFvs targeting atherosclerotic lesions. J Biol Chem 2006, 281(52):40135-40143.
57. Berezovski MV, Lechmann M, Musheev MU, Mak TW, Krylov SN: Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 2008, 130(28):9137-9143.
58. Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE: Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 2011, 121(6):2383-2390.
59. Senter PD: Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009, 13(3):235-244.
60. Regino C, Wong K, Milenic D, Holmes E, Garmestani K, Choyke P, Brechbiel M: Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. Curr Radiopharm 2009, 2(1):9-17.
61. Sievers EL, Linenberger M: Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001, 13(6):522-527.
62. Stebbing J, Copson E, O'Reilly S: Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev 2000, 26(4):287-290.
63. Kanter G, Yang J, Voloshin A, Levy S, Swartz JR, Levy R: Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood 2007, 109(8):3393-3399.
64. Begent R, Chester K: Single-chain Fv antibodies for targeting cancer therapy. Biochem Soc Trans 1997, 25(2):715-716.
65. Clark M: Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today 2000, 21(8):397-402.
66. Elsässer-Beile U, Reischl G, Wiehr S, Bühler P, Wolf P, Alt K, Shively J, Judenhofer MS, Machulla HJ, Pichler BJ: PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009, 50(4):606-611.
67. Veiseh O, Gunn JW, Zhang M: Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 2010, 62(3):284-304.
68. Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J: Use of a monoclonal antibody (B72. 3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens. Hum Pathol 1986, 17(5):501-513.
69. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450(7173):1235-1239.
70. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 1983, 43(4):1809-1818.
71. Wang M, Liu A, Garcia FU, Rhim JS, Stearns ME: Growth of HPV-18 immortalized human prostatic intraepithelial neoplasia cell lines. Influence of IL-10, follistatin, activin-A, and DHT. Int J Oncol 1999, 14(6):1185-1195.
72. Hayward S, Dahiya R, Cunha G, Bartek J, Deshpande N, Narayan P: Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro CellDev Biol Anim 1995, 31(1):14-24.
73. Jiang M, Strand DW, Fernandez S, He Y, Yi Y, Birbach A, Qiu Q, Schmid J, Tang DG, Hayward SW: Functional remodeling of benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells. Stem Cells 2009, 28(2):344-356.
74. Stone K, Mickey D, Wunderli H, Mickey G, Paulson D: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978, 21(3):274-281.
75. Kaighn M, Narayan KS, Ohnuki Y, Lechner J, Jones L: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979, 17(1):16-23.
76. Bello D, Webber M, Kleinman H, Wartinger D, Rhim J: Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinog 1997, 18(6):1215-1223.
77. Silver DA, Pellicer I, Fair WR, Heston W, Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997, 3(1):81-85.
78. Langan TJ, Nyakubaya VT, Casto LD, Dolan TD, Archer-Hartmann SA, Yedlapalli SL, Sooter LJ, Holland LA: Assessment of aptamer-steroid binding using stacking-enhanced capillary electrophoresis. Electrophoresis 2012, 33(5):866-869.